A search to identify new mechanisms of isoniazid resistance in Mycobacterium bovis led to the isolation of mutants defective in mycothiol biosynthesis due to mutations in genes coding for the glycosyltransferase (mshA) or the cysteine ligase (mshC). These mutants showed low-level resistance to isoniazid but were highly resistant to ethionamide. This study further illustrates that mutations in mycothiol biosynthesis genes may contribute to isoniazid or ethionamide resistance across mycobacterial species.
Drug resistance in Mycobacterium tuberculosis has been a growing concern since the introduction of the first chemotherapy for tuberculosis (TB). Resistance to the first-line antituberculosis drug isoniazid (INH) emerged less than a year after its introduction as a new TB drug in 1952 (8, 10) . Now, almost one-third of new TB patients are infected with an INH-resistant (INH r ) TB strain. Determination of all the factors causing INH resistance would be a tremendous help in the diagnosis of drug resistance, which would then lead to proper treatment for TB patients. In a recent study, almost 20% of INH r clinical strains had no mutations in genes known to confer INH resistance (3). Previously, to identify new mechanisms of INH resistance in mycobacteria we isolated spontaneous mutants of M. smegmatis (9, 14) , M. bovis BCG (14) , and M. tuberculosis (12) that were coresistant to INH and the second-line anti-TB drug ethionamide (ETH). ETH, an analog of INH, has the same mechanism of action as INH but a different mechanism of activation. Both INH and ETH are prodrugs that are activated by the catalase-peroxidase KatG (4, 16) and the monooxygenase EthA (1, 2), respectively, and they both target the NADH-dependent enoyl-ACP reductase InhA (13) . The strategy of isolating mutants coresistant to both INH and ETH allowed us to eliminate mutants that would be defective in the activation steps. In M. smegmatis and in M. bovis BCG, the INH r and ETH-resistant (ETH r ) mutants isolated had mutations in the type II NADH dehydrogenase NdhII (9, 14) . When the same selection strategy was applied to M. tuberculosis, we were surprised to discover that none of the mutants isolated had mutations in ndh. Instead, all the INH r and ETH r mutants had mutations in mshA, a gene encoding the glycosyltransferase involved in mycothiol biosynthesis (12) . Puzzled by the different mutants obtained from the same selection strategy in the nonpathogenic M. smegmatis and M. bovis BCG (ndh mutants) and virulent M. tuberculosis (mshA mutants), we went on to perform the same screening in virulent M. bovis Ravenel.
Spontaneous mutants coresistant to INH and ETH were isolated by plating M. bovis Ravenel on Middlebrook 7H10 plates supplemented with 10% (vol/vol) oleic acid-albumindextrose-catalase enrichment, 0.2% (vol/vol) glycerol, 0.05% (vol/vol) tyloxapol, INH (0.1 mg/liter), and ETH (10 mg/liter). The frequency of mutant isolation was 6 ϫ 10 Ϫ7 . Colonies were streaked on plates containing INH (0.1 mg/liter) and ETH (10 mg/liter) to verify drug resistance. All of the 10 mutants had confirmed resistance to INH and ETH. The MICs for INH and ETH were determined for each mutant by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay for INH (7) or the resazurin assay for ETH (6) and confirmed by incubating each mutant (Ϸ10 4 cells) in medium containing different concentrations of drugs at 37°C for 3 weeks (the MIC was defined as the lowest concentration of drug that prevented growth). All the mutants were highly resistant to ETH but had different levels of INH resistance (Table 1) . Genomic DNA was extracted (5) , and the genes known to confer either INH and/or ETH resistance (katG, ethA, inhA [gene and promoter region], ndh, and mshA) were PCR amplified and sequenced. None of the mutants had mutations in katG, ethA, inhA, or ndh, but 5/10 mutants had mutations in mshA ( Table 1 ). The mshA mutations consisted of deletions of a single base pair or of several amino acids (48-and 56-bp deletions). Mycothiol levels were measured as described previously (11) . Briefly, cell pellets of stationary-phase cultures were treated with mBBr reagent (20 mM HEPES [pH 8] plus 2 mM monobromobimane in acetonitrile-water [1/1, vol/vol]) at 60°C for 15 min. After centrifugation, the supernatants were treated with 5 M methane sulfonic acid and frozen. Quantification of the mycothiol-bimane derivative was achieved by analyzing the samples on an high-performance liquid chromatograph coupled to a fluorescence detector. The M. bovis mshA mutants lost 99% of their mycothiol content compared to wild type ( To identify what mutation(s) was responsible for the drug resistance phenotype in the non-mshA mutants, whole-genome sequencing of the parent strain M. bovis Ravenel and one mutant, mc 2 4980, was performed using the high-throughput Illumina Solexa system (15) . A single base pair difference in the 2 strains was found that mapped to mshC, a gene encoding the cysteine ligase involved in mycothiol biosynthesis. The identified mshC mutation (P47R) was reconfirmed by sequencing the mshC gene from a different genomic DNA preparation of mc 2 4980. Sequence analysis revealed that the other 4 nonidentified spontaneous INH r and ETH r mutants also had various mutations in mshC (Table 1) . Two mutants had the same 3-bp deletion resulting in 1 amino acid deletion (D86), while the other 2 mutants had the identical base pair change for a G54S amino acid change. All mshC mutants had lost more than 93% of their mycothiol level compared to the parental strain (Table 1) . To prove that the mshC mutations were the cause of the resistance to ETH and INH and loss of mycothiol, we transformed mc 2 4980 with pMV361::mshC Bo , an integrative plasmid with an hsp60 promoter driving M. bovis mshC. The transformant, mc 2 4998, regained all three phenotypes. Thus, we have established that a mutation in mshC is sufficient to confer resistance to ETH and low resistance to INH and represents a novel resistance allele.
This study confirms that in vitro-induced mutations in mshA and mshC are indeed associated with high-level resistance to ETH in pathogenic mycobacterial species, although any mutation in mshA found in clinical isolates should be analyzed carefully, since wild-type mycobacterial strains can mutate mshA without losing their drug susceptibility phenotype. 
